Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDegLira plus oral antidiabetic drugs vs CSII for short-term intensive therapy in newly diagnosed type 2 diabetes
ChiCTR2500111276Phase 4Not yet recruiting
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Oct 2025
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial of insulin degludec + liraglutide, insulin degludec and liraglutide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Nanfang Hospital, Southern Medical University. Primary endpoint: Glycemic remission rate at 3 months after treatment discontinuation. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2500111276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500111276.